GKOS
GLAUKOS Corp
Overview
GLAUKOS Corp is a Healthcare company operating in Medical Devices with a $7.71B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 28, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-04-2925 Q&A exchanges
- Q4 FY2025Earnings2026-02-1722 Q&A exchanges
- Q3 FY2025Earnings2025-10-3019 Q&A exchanges
- Q2 FY2025Earnings2025-07-3120 Q&A exchanges
- Q1 FY2025Earnings2025-04-3027 Q&A exchanges
- Q4 FY2024Earnings2025-02-2128 Q&A exchanges
- Q3 FY2024Earnings2024-11-0433 Q&A exchanges
- Q2 FY2024Earnings2024-07-3122 Q&A exchanges
- Q1 FY2024Earnings2024-05-0124 Q&A exchanges
- Q4 FY2023Earnings2024-02-2125 Q&A exchanges
- Q3 FY2023Earnings2023-11-0129 Q&A exchanges
- Q2 FY2023Earnings2023-08-0217 Q&A exchanges
- Q1 FY2023Earnings2023-05-0321 Q&A exchanges
- Q4 FY2022Earnings2023-02-2235 Q&A exchanges
- Q3 FY2022Earnings2022-11-0417 Q&A exchanges
- Q2 FY2022Earnings2022-08-0321 Q&A exchanges
- Q1 FY2022Earnings2022-05-0422 Q&A exchanges
- Q4 FY2021Earnings2022-02-2326 Q&A exchanges
- Q3 FY2021Earnings2021-11-0725 Q&A exchanges
- Q2 FY2021Earnings2021-08-0830 Q&A exchanges
- Q1 FY2021Earnings2021-05-0814 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-28EPS— vs $-0.21—Rev— vs ——EODHD
- Q1 FY20262026-05-05EPS$-0.18 vs $-0.28+35.7%Rev$150.6M vs ——EODHD
- Q4 FY20252026-02-16EPS$-0.90 vs $-0.21-100.0%Rev$143.1M vs ——EODHD
- Q3 FY20252025-10-28EPS$-0.16 vs $-0.26+38.5%Rev$133.5M vs ——EODHD
- Q2 FY20252025-07-29EPS$-0.24 vs $-0.26+7.7%Rev$124.1M vs ——EODHD
- Q1 FY20252025-04-28EPS$-0.22 vs $-0.36+38.1%Rev$106.7M vs ——EODHD
- Q4 FY20242025-02-18EPS$-0.40 vs $-0.39-3.0%Rev$105.5M vs ——EODHD
- Q3 FY20242024-11-03EPS$-0.28 vs $-0.48+41.7%Rev$96.7M vs ——EODHD
- Q2 FY20242024-07-30EPS$-0.52 vs $-0.51-2.0%Rev$95.7M vs ——EODHD
- Q1 FY20242024-04-30EPS$-0.70 vs $-0.57-22.8%Rev$85.6M vs ——EODHD
- Q4 FY20232024-02-20EPS$-0.63 vs $-0.55-14.5%Rev$82.4M vs ——EODHD
- Q3 FY20232023-10-31EPS$-0.50 vs $-0.55+9.1%Rev$78.0M vs ——EODHD
- Q2 FY20232023-08-01EPS$-0.55 vs $-0.550.0%Rev$80.4M vs ——EODHD
- Q1 FY20232023-05-02EPS$-0.59 vs $-0.58-1.7%Rev$73.9M vs ——EODHD
- Q4 FY20222023-02-21EPS$-0.53 vs $-0.55+3.6%Rev$71.2M vs ——EODHD
- Q3 FY20222022-11-01EPS$-0.45 vs $-0.52+13.5%Rev$71.3M vs ——EODHD
- Q2 FY20222022-08-02EPS$-0.83 vs $-0.44-88.6%Rev$72.7M vs ——EODHD
- Q1 FY20222022-05-03EPS$-0.38 vs $-0.51+25.5%Rev$67.7M vs ——EODHD
- Q4 FY20212022-02-21EPS$-0.31 vs $-0.37+16.2%Rev$73.2M vs ——EODHD
- Q3 FY20212021-11-03EPS$-0.21 vs $-0.24+12.5%Rev$74.7M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-28 | — | $-0.21 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $-0.18 | $-0.28 | +35.7% | $150.6M | — | — | EODHD |
| Q4 FY2025 | 2026-02-16 | $-0.90 | $-0.21 | -100.0% | $143.1M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $-0.16 | $-0.26 | +38.5% | $133.5M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $-0.24 | $-0.26 | +7.7% | $124.1M | — | — | EODHD |
| Q1 FY2025 | 2025-04-28 | $-0.22 | $-0.36 | +38.1% | $106.7M | — | — | EODHD |
| Q4 FY2024 | 2025-02-18 | $-0.40 | $-0.39 | -3.0% | $105.5M | — | — | EODHD |
| Q3 FY2024 | 2024-11-03 | $-0.28 | $-0.48 | +41.7% | $96.7M | — | — | EODHD |
| Q2 FY2024 | 2024-07-30 | $-0.52 | $-0.51 | -2.0% | $95.7M | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $-0.70 | $-0.57 | -22.8% | $85.6M | — | — | EODHD |
| Q4 FY2023 | 2024-02-20 | $-0.63 | $-0.55 | -14.5% | $82.4M | — | — | EODHD |
| Q3 FY2023 | 2023-10-31 | $-0.50 | $-0.55 | +9.1% | $78.0M | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $-0.55 | $-0.55 | 0.0% | $80.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $-0.59 | $-0.58 | -1.7% | $73.9M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $-0.53 | $-0.55 | +3.6% | $71.2M | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $-0.45 | $-0.52 | +13.5% | $71.3M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $-0.83 | $-0.44 | -88.6% | $72.7M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $-0.38 | $-0.51 | +25.5% | $67.7M | — | — | EODHD |
| Q4 FY2021 | 2022-02-21 | $-0.31 | $-0.37 | +16.2% | $73.2M | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-0.21 | $-0.24 | +12.5% | $74.7M | — | — | EODHD |
Source: EODHD. GKOS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks GKOS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 4 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.91 | $3.71 | +5.5% | -1.2% | -1.9% |
| Q4 FY2026 | $4.25 | $3.63 | +17.1% | -1.7% | +1.0% |
| Q3 FY2026 | $4.25 | $3.72 | +14.2% | +7.1% | +6.4% |
| Q2 FY2026 | $4.04 | $3.71 | +8.9% | -1.3% | +1.1% |
| Q1 FY2025 | $3.85 | $3.71 | +3.9% | +4.7% | +2.6% |
| Q4 FY2025 | $3.91 | $3.69 | +5.9% | +7.1% | +9.4% |
| Q3 FY2025 | $3.95 | $3.73 | +6.0% | -0.6% | +1.7% |
| Q2 FY2025 | $4.27 | $3.85 | +11.0% | +2.0% | +2.1% |
| Q1 FY2024 | $4.25 | $3.75 | +13.4% | -2.1% | -1.2% |
| Q4 FY2024 | $4.24 | $3.91 | +8.5% | +4.0% | +3.4% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Thomas William BurnsCEO5 mo1 callCurrentSample
CEO since 2026 • 1/2 beats (50%) • last call held guidance Q3 FY2026
- Alex R ThurmanCFO3 mo16 callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • guidance suspended Q1 FY2026
- Joseph E GilliamCOO5 mo21 callsCurrentSample
COO since 2026 • 2/2 beats (100%) • last guidance raise Q2 FY2026
- Tomas NavratilCHIEF DEVELOPMENT OFFICER4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • guidance suspended Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GKOS.
$ curl https://api.spokenalpha.com/v1/companies/GKOSFAQ
Frequently asked about GKOS
Where can I find GLAUKOS Corp's (GKOS) earnings call transcripts?
Spoken Alpha indexes GKOS's earnings call transcripts at https://spokenalpha.com/companies/GKOS. Each call links to attributed speakers and parsed analyst Q&A. GLAUKOS Corp's own investor relations page is at https://investors.glaukos.com/overview/default.aspx.
When was GLAUKOS Corp's most recent earnings call?
GLAUKOS Corp (GKOS) held its most recent earnings call on 2026-04-29, covering fiscal Q1 2026.
What sector is GKOS in?
GLAUKOS Corp (GKOS) operates in the Healthcare sector (Medical Devices industry).